Mirae Asset Global Investments Co. Ltd. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 27.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,336 shares of the company’s stock after buying an additional 504 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Kymera Therapeutics were worth $114,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in KYMR. Price T Rowe Associates Inc. MD grew its position in shares of Kymera Therapeutics by 18.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock worth $254,548,000 after acquiring an additional 996,300 shares during the last quarter. Vanguard Group Inc. boosted its stake in Kymera Therapeutics by 19.2% during the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock worth $191,635,000 after purchasing an additional 769,486 shares during the period. Avoro Capital Advisors LLC grew its position in Kymera Therapeutics by 3.0% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,888,888 shares of the company’s stock worth $156,333,000 after purchasing an additional 113,888 shares during the last quarter. Artal Group S.A. boosted its stake in shares of Kymera Therapeutics by 19.6% during the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock worth $121,691,000 after buying an additional 496,400 shares during the period. Finally, Jennison Associates LLC acquired a new stake in shares of Kymera Therapeutics during the first quarter worth about $17,122,000.

Kymera Therapeutics Trading Up 1.3 %

KYMR stock opened at $47.07 on Tuesday. The firm has a 50 day moving average of $46.98 and a 200-day moving average of $40.83. The company has a market cap of $2.91 billion, a price-to-earnings ratio of -20.12 and a beta of 2.21. Kymera Therapeutics, Inc. has a 12-month low of $13.85 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 28.05% and a negative net margin of 191.26%. The firm had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same period in the previous year, the firm posted ($0.90) earnings per share. Kymera Therapeutics’s revenue was down 20.9% on a year-over-year basis. Sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KYMR has been the subject of several analyst reports. B. Riley upped their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, July 9th. UBS Group cut their price target on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday. Wells Fargo & Company lifted their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $50.93.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. Insiders own 15.82% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.